Sequential use of bevacizumab and cetuximab in patients with K-RAS wild type advanced colorectal cancer.

被引：0
|
作者：
Akbulut, Hakan
Gercik, Onay
Icli, Fikri
Mizrak, Dilsa
Demirkazik, Ahmet
Onur, Handan
Senler, Filiz Cay
Utkan, Gungor
机构：
[1] Ankara Univ, Dept Med Oncol, TR-06100 Ankara, Turkey
[2] Ankara Univ, Sch Med, TR-06100 Ankara, Turkey
[3] Ankara Univ, TR-06100 Ankara, Turkey
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.e14681
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14681
引用
收藏
页数：1
相关论文
共 50 条
  • [1] K-ras mutations and benefit from cetuximab in advanced colorectal cancer
    Karapetis, Christos S.
    Khambata-Ford, Shirin
    Jonker, Derek J.
    O'Callaghan, Chris J.
    Tu, Dongsheng
    Tebbutt, Niall C.
    Simes, R. John
    Chalchal, Haji
    Shapiro, Jeremy D.
    Robitaille, Sonia
    Price, Timothy J.
    Shepherd, Lois
    Au, Heather-Jane
    Langer, Christiane
    Moore, Malcolm J.
    Zalcberg, John R.
    NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (17): : 1757 - 1765
  • [2] K-ras Mutations and Cetuximab in Colorectal Cancer
    Albitar, Maher
    Yeh, Chenhsiung
    Ma, Wanlong
    NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (08): : 834 - 834
  • [3] Quality of Life in Patients With K-RAS Wild-Type Colorectal Cancer
    Ringash, Jolie
    Au, Heather-Jane
    Siu, Lillian L.
    Shapiro, Jeremy D.
    Jonker, Derek J.
    Zalcberg, John R.
    Moore, Malcolm J.
    Strickland, Andrew
    Kotb, Rami
    Jeffery, Mark
    Alcindor, Thierry
    Ng, Siobhan
    Salim, Muhammad
    Sabesan, Sabe
    Easaw, Jay C.
    Shannon, Jenny
    El-Tahche, Fabyolla
    Walters, Ian
    Tu, Dongsheng
    O'Callaghan, Christopher J.
    CANCER, 2014, 120 (02) : 181 - 189
  • [4] K-ras mutation in colorectal cancer treated with cetuximab
    Barbareschi, M.
    Girlando, S.
    Soini, B.
    Cuorvo, L.
    Fasanella, S.
    Cantaloni, C.
    Piccolo, A.
    Prosdocimi, F.
    Galligioni, E.
    Dalla Palma, P.
    VIRCHOWS ARCHIV, 2009, 455 : 396 - 396
  • [5] Biweekly cetuximab and first-line chemotherapy in chinese patients with k-ras wild-type colorectal cancers
    Chan, Wing-Lok
    Lee, Victor Ho Fun
    Siu, Wai Kwan Steven
    Ho, Pui Ying Patty
    Liu, Rico King Yin
    Leung, To Wai
    SOUTH ASIAN JOURNAL OF CANCER, 2014, 3 (03) : 175 - 178
  • [6] Sensitivity of detection of K-ras mutations in colorectal cancer.
    Bennett, DH
    Carpenter, K
    Durrant, L
    Kalsheker, N
    Hardcastle, JD
    GASTROENTEROLOGY, 1996, 110 (04) : A491 - A491
  • [7] Prognostic stratification of k-RAS wild type colorectal cancer patients receiving irinotecan-cetuximab treatment: Preliminary results of a prospective study
    Scartozzi, Mario
    Giampieri, Riccardo
    Mandolesi, Alessandra
    Abouelkhair, Khaled Mahmoud
    Loretelli, Cristian
    Del Prete, Michela
    Faloppi, Luca
    Bittoni, Alessandro
    Bianconi, Maristella
    Cecchini, Luca
    Ibrahim, Ezzeldin M.
    Bearzi, Italo
    Cascinu, Stefano
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [8] Correlation between K-ras mutations status and benefit from cetuximab treatment in advanced colorectal cancer
    Xie, L.
    Lai, R.
    Wu, X.
    Zhang, S.
    Tang, X.
    Chen, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [9] Molecular biomarkers for a prognostic stratification of K-RAS wild type colorectal cancer patients receiving irinotecan-cetuximab: Preliminary results of a prospective study
    Scartozzi, M.
    Giampieri, R.
    Mandolesi, A.
    Abouelkhair, K. M.
    Loretelli, C.
    Del Prete, M.
    Faloppi, L.
    Bianconi, M.
    Ibrahim, E. M.
    Cascinu, S.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S562 - S562
  • [10] Expression of EGFR, VEGF, and K-ras mutation as predictors for response of cetuximab in colorectal cancer patients
    Hwang, D.
    Jung, E.
    Cho, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345